 Patent Application Title |
Patent App Num. |
Date |
 Method and composition to improve absorption of therapeutic agents | 20130122098 | 20130516 |
 A tablet with an enhanced dissolution profile for a medicinally active ingredient such as aspirin and methods for making the tablet. The tablet comprises a blend of crystals of the medicinally active ingredient and a dissolution aid such as sodium or calcium carbonate or bicarbonate that coats the crystals upon co-milling. The blend is then compressed to form tablets that have an enhanced dissolution profile for the medicinally active ingredient.
... |
| Anti-flush compositions | 20130115289 | 20130509 |
 Disclosed are pharmaceutical compositions having a portion of aspirin for intraoral release and another aspirin for gastrointestinal release. The compositions can further include niacin. Methods of using such compositions to treat diseases or conditions suitably treated by niacin are also provided which result in reduced flushing.
... |
| Methods of treatment of patients at increased risk of development of ischemic events and compounds hereof | 20130040898 | 20130214 |
 The present invention relates to compounds for treatment that protects the endothelium, prevents pathologic thrombus formation in the microcirculation and preserves platelet number and function and thus may be related to treatment or prevention of ischemic events in patients with cardiovascular disease. The present invention is particularly useful for patients having or being at increased risk of development of an ischemic event such as an acute myocardial infarction and/or no-reflow phenomena and/or ischemia-reperfusion injury by administration of agent(s) modulating and/or preserving endothelial integrity. The compounds may be administered in combination with standard treatment of acute cardiovascular ischemic events such as Platelet inhibitors such as aspirin (ASA), Thienopyridins, GPIIb/IIIa inhibitors), Parenteral anticoagulants such as unfractioned heparin (UFH), bivalirudin, enoxaparin, and fondaparinux, Verapamil, Adenosine, Sodium nitroprusside, Nitroglycerin, Epinephrine,... |
| Formulations from natural products, turmeric, paclitaxel, and aspirin | 20130029922 | 20130131 |
 The invention provides novel compounds and formulations of turmeric oil, fish oil, aspirin and anti-cancer drugs (paclitaxel) having anti-inflammatory, analgesic and/or anti-cancer activity.
... |
| Analgesic composition and method of making the same | 20120316140 | 20121213 |
 A soluble aspirin composition, comprising: (i) granules including aspirin, heat-treated bicarbonate salt, pharmaceutically-acceptable resin and surfactant, in mixture with: (ii) crystalline particles of pharmaceutically-acceptable acid; and (iii) crystalline particles of heat-treated bicarbonate salt; wherein the soluble aspirin composition when introduced to water undergoes reaction of the crystalline particles of pharmaceutically-acceptable acid with the heat-treated bicarbonate salt and the aspirin to effect effervescing action and disintegration of the granules with conversion of the aspirin to an acetylsalicylate compound of the bicarbonate salt cation so that the composition rapidly dissolves in the water without occurrence of undissolved residue. The composition is solublizable within 30 seconds in cool to cold water to provide an effervescent analgesic solution that can be readily orally administered to an individual in need of... |
Subscribe to updates on this page: Aspirin RSS  |
| Complex formulation comprising aspirin coated with barrier containing hydrophobic additive, and hmg-coa reductase inhibitor | 20120301549 | 20121129 |
| Provided is a complex formulation for the prevention or treatment of cardiovascular diseases, comprising: a) aspirin coated with a barrier containing a hydrophobic additive; and b) an HMG-CoA reductase inhibitor, which has improved storage stability by preventing the deterioration in the stability of HMG-CoA reductase which is caused by salicylic acid, thereby being used in the treatment of hypertension and hypercholesterolemia.
... |
| Use of docosatrienes, resolvins, and their stable analogs in the treatment of airway diseases and asthma | 20120264713 | 20121018 |
| The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the... |
| Synergistic anti-inflammatory and antioxidant dietary supplement compositions | 20120220657 | 20120830 |
| Disclosed herein are novel dietary supplement compositions comprising enriched 3-O-acetyl-11-keto-β-boswellic acid and enriched demethylated curcuminoids, wherein the composition exhibits anti-inflammatory, antiulcerogenic and anti-oxidant activities. Also disclosed are novel compositions comprising enriched 3-O-acetyl-11-keto-β-boswellic acid, enriched demethylated curcuminoids that have a synergistic effect on specific inhibition of—COX-2 and 5-LOX activity and optionally containing glucosamine, resveratrol, garlic extract, chondroitin, methlysulphonymethane, bromelain, serratiopeptidase, quercitine, gallic acid, caffeic acid, green tea extract, aspirin and ibuprofen.
... |
| Method for treating a patient in need of aspirin therapy | 20120177736 | 20120712 |
| The present disclosure is directed to a method for treating a disease or disorder in a patient at risk of developing an NSAID-associated ulcer by administering to the patient in need thereof a pharmaceutical composition in unit dosage form comprising aspirin, or a pharmaceutically acceptable salt thereof, and an acid inhibitor to the at risk patient and thereby decreasing the patient's risk of developing an ulcer.
... |
| Compositions for reducing the incidence of drug induced arrhythmia | 20120178724 | 20120712 |
| In accordance with the present invention, novel methods and formulations are provided for treating and preventing the incidence of drug-induced pro-arrhythmia, including torsades de pointes. The methods and formulations comprise a combination of a drug that induces torsade de pointes, such as Class III antiarrhythmics, certain antimicrobials, antihistamines, antidepressants, antipsychotics, diuretics, with an aspirin and/or a statin. In certain embodiments, the compositions and methods for treatment comprise azimilide and aspirin and/or a statin. These compositions may be administered by different routes, including orally. In certain embodiments where the antiarrhythmic is azimilide it may be administered orally in a dose of about 25 mg to about 300 mg.
... |
| Aspirin assay | 20120164756 | 20120628 |
| The invention describes a method for monitoring and detecting non-therapeutic, therapeutic and toxic concentrations of aspirin in individuals which uses the urinary salicylic acid to salicyluric acid ratio.
... |
| Compositions and methods for organ preservation | 20120122816 | 20120517 |
| The invention relates to reducing, preventing or reversing organ damage, reducing and/or preventing stem cell damage and/or death, enhancing organ preservation and/or survival, or enhancing stem cell preservation and/or survival comprising administering a compound of formula A, a compound of any one of formulae 1-49 or I-III, a lipoxin compound, an oxylipin compound, or a combination of aspirin and an omega-3 fatty acid.
... |
| Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the same | 20120015032 | 20120119 |
| The present invention relates to a chronotherapeutically combined pharmaceutical formulation for preventing and treating cardiovascular diseases, which is based on the principle of administering a plurality of drugs at certain time intervals (chronotherapy). Specifically, the combined pharmaceutical formulation comprises a HMG-CoA reductase inhibitor, such as simvastatin, and aspirin. Because the combined pharmaceutical formulation was developed based on the principle of administering drugs at certain time intervals, so-called chronotherapy, it shows an excellent effect of preventing or treating cardiovascular disease compared to those of the individual administration and simultaneous administration of the single preparations. Also, it is a once-daily dosage form which increases the medication compliance of patients. Particularly, even though the content of aspirin in the combined pharmaceutical formulation is reduced, the platelet aggregation inhibitory effect... |
Subscribe to updates on this page: Aspirin RSS |
| Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor | 20120009172 | 20120112 |
| alone or in combination with a second agent which can be aspirin or a thrombolytic agent.
... |
| Method for treating a patient in need of aspirin therapy | 20110008432 | 20110113 |
| The present disclosure is directed to a method for treating a disease or disorder in a patient at risk of developing an NSAID-associated ulcer by administering to the patient in need thereof a pharmaceutical composition in unit dosage form comprising aspirin, or a pharmaceutically acceptable salt thereof, and an acid inhibitor to the at risk patient and thereby decreasing the patient's risk of developing an ulcer.
... |
| Novel polymorph of acetylsalicylic acid, and methods of making and using the same | 20100331285 | 20101230 |
| A polymorph of aspirin is provided by the present invention. Methods of making and using the same are also provided.
... |
| Methods of screening for compounds that modulate tafia activity, compounds, and methods of using the compounds | 20100310540 | 20101209 |
| Provided are methods of screening compounds for any aspirin-related activity other than TAFI inhibition, and also for non-inhibition of TAFI. Compounds identified by the screening methods can be used to treat, prevent or manage in a patient pain, fever, colon cancer, pancreatic cancer or an inflammatory, platelet aggregation, fibrinolytic or hemorrhagic disease or disorder. Also provided is a method of evaluating test compounds for TAFI inhibitory activity wherein the TAFI inhibitory activity of these test compounds is compared to the TAFI inhibitory activity of aspirin or its derivatives or metabolites. Further provided is a method of treating, preventing or managing in a patient, a hemorrhagic or thrombotic disease or disorder with high dose aspirin or aspirin derivatives or metabolites. Also contemplated is a method of treating,... |
| Compositions and methods for reducing hepatotoxicity associated with drug administration | 20100297271 | 20101125 |
| The present invention relates to the discovery that acetylsalicylic acid (ASA or aspirin), salicylic acid (SA) and related salicylate esters and their pharmaceutically acceptable salts, when coadministered in effective amounts with a drug or other bioactive agent which typically (in the absence of the salicylate compound) produces significant hepatotoxicity as a secondary indication, will substantially reduce or even eliminate such hepatotoxicity. Favorable therapeutic intervention results from the use of the present invention having the effect of reducing hepatotoxicity associated with the administration of certain drugs and other bioactive agents and in certain instances of allowing the administration of higher doses of a compound which, without the coadministration, would produce hepatotoxicity which limits or even negates the therapeutic value of the compound.
... |
| Treatment of aspirin resistance with betaine and/or betaine enriched molasses | 20100292327 | 20101118 |
| Use of glycine betaine as therapeutically active ingredient for the preparation of a medicament and/or a nutritional product and/or a dietary supplement for treating human resistant to a compound selected from the group consisting of aspirin, clopidogrel, thienopyridines and combinations thereof, who suffers from a disease requiring the administration of a compound selected from the group consisting of aspirin, clopidogrel, thienopyridines and combinations thereof, or who is at risk of suffering of said disease, whereby the medicament comprises an effective amount of glycine betaine for decreasing by at least 10%, advantageously at least 20% the resistance of said patient to said compound selected from the group consisting of aspirin, clopidogrel, thienopyridines and combinations thereof
... |
| Anti-pyretic vasodilators | 20100292280 | 20101118 |
| The invention provides vasodilating medication as means for lowering fever when administered to humans in need of such treatment. In particular, the use of B3 vitamin substances and Nitric Oxide-donor ingredients in compositions intended for use in reducing fever is introduced. The core composition substances can be used effectively on their own. Yet, in combination with anti-pyretic substances such as Aspirin, Acetaminophen, and Ibuprofen, the present invention enables the use of reduced dosage of composing substances for achievement of desired fever reduction effect. In addition, an optional addition of sweat inducing plant extracts in any of the noted compositions leads to a synergistic effect of reducing fever by increase of both skin blood flow and perspiration.
... |
| Method and composition to improve absorption of therapeutic agents | 20100286100 | 20101111 |
| A tablet with an enhanced dissolution profile for a medicinally active ingredient such as aspirin and methods for making the tablet. The tablet comprises a blend of crystals of the medicinally active ingredient and a dissolution aid such as sodium or calcium carbonate or bicarbonate that coats the crystals upon co-milling. The blend is then compressed to form tablets that have an enhanced dissolution profile for the medicinally active ingredient.
... |
| Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine | 20100286099 | 20101111 |
| A water-soluble aspirin-theanine cocrystal composition which includes a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer associated with the quantity of acetylsalicylic acid. The composition may be created by a method including the steps of: (i) providing a quantity of acetylsalicylic acid; (ii) adding a quantity of a theanine enantiomer to the quantity of acetylsalicylic acid to form a mixture comprising the quantity of acetylsalicylic acid and the enantiomer of theanine; (iii) wetting the mixture; and (iv) grinding the mixture for a length of time sufficient to produce a dried crystalline mass. The water-soluble cocrystal composition is suitable for intravenous administration, preferably to humans.
... |
| Method for delivering a combination of resveratrol and aspirin for use in treatment and prevention of vascular disease | 20100255088 | 20101007 |
| A method for delivering a composition for use in treatment and prevention of vascular disease by providing a vehicle for delivery of the composition to an individual, wherein the composition contains a combination of aspirin and resveratrol; administering the vehicle to the mouth of the individual, wherein the vehicle melts at the body temperature of the individual such that the aspirin and resveratrol is absorbed thru the oral mucosa and delivered directly into the inidvidual's bloodstream; and a related melting capsule comprised of a material that has the same melting point as the human body temperature and includes aspirin in the range of 81 to 325 mg and resveratrol in the range of 10 to 300 mg.
... |
| Methods and kits for detection of thromboxane a2 metabolites | 20100227417 | 20100909 |
| Methods, compositions and kits are provided for measuring aspirin's anti-thrombotic effectiveness on a subject. Included are a novel assay for quickly and specifically measuring TxA2 metabolite levels in urine and correlating the levels with aspirin dose in a subject. The methods, compositions and kits utilize a novel anti TxA2 metabolite antibody.
... |
| Aspirin-triggered lipid mediators | 20100216882 | 20100826 |
| Aspirin triggered lipid mediators (ATLMs) are disclosed which are useful for the treatment of prevention of inflammation associated with diseases, including ischemia.
... |
| New no-donor aspirin derivatives | 20100210694 | 20100819 |
| The present invention refers to new NO-donors aspirin derivatives, a process for their preparation and pharmaceutical compositions containing them.
... |
| Dual channel aspirated detector | 20100194575 | 20100805 |
| A dual channel aspiring smoke detector includes ultrasonic flow sensors associated with each channel. The detector can make determinations of smoke levels associated with respective channels as well as rates of flow through each channel. Respective alarm or trouble indicators can be output in response to determined smoke levels as well as determined flow rate. The detector can be used as a stand alone device or part of a fire alarm system.
... |
| Oral antidepressant formulation | 20100189797 | 20100729 |
| Oral antidepressant formulation comprising a means for controlling the release of the pharmaceutically acceptable antidepressant active agent selected from the group consisting of SSRI agents, SNRIs (serotonin noradrenaline reuptake inhibitors), CRF antagonists, NK1 antagonists, NK2 antagonists, NK3 antagonists and combinations thereof, with respect to the release of the compound selected from the group consisting of acetylsalicylic acid, salts and esters of acetylsalicylic acid, diaspirin, and mixtures thereof.
... |
| Self-contained multivariate optical computing and analysis systems | 20100182600 | 20100722 |
| An optical analysis system includes a light source configured to radiate a first light along a first ray path; a modulator disposed in the first ray path, the modulator configured to modulate the first light to a desired frequency; a spectral element disposed proximate the modulator, the spectral element configured to filter the first light for a spectral range of interest of a sample; a cavity in communication with the spectral element, the cavity configured to direct the first light in a direction of the sample; a conical mirror configured to convert the first light reflecting from the sample into a second light, the cavity being further configured to direct the second light; a beamsplitter configured to split the second light into a first beam and... |
| Formulation of aspirin that is stable and showing minimal hydrolysis for parenteral adminstration for the treatment of cardiovascular and other disease states | 20100173875 | 20100708 |
| Disclosed herein are ways to solubilize aspirin for parenteral administration containing aspirin and a diluent NNDMA (N,N-Dimethylacetamide) useful in the treatment of acute coronary syndromes as well as other disease states. The solution so constituted is stable at room temperature for prolonged periods without decomposition and avoids significant hydrolysis of the aspirin and thus the loss of the anti-platelet action when stored.
... |
| Emergency dose medication administration device | 20100125242 | 20100520 |
| An emergency dose medication administration device suitable for administration of an effervescent therapeutic composition, such as a soluble aspirin product that when mixed with water or other aqueous medium forms an effervescent composition for administration to a patient. The administration device of the invention includes separate compartments separated from one another by a barrier member, in which at least one of the compartments includes a bellowed portion which is expansible upon intermixing of materials from the respective compartments of the device, when the barrier member is pierced by a manually actuatable piercing element that includes a passage for administration of the effervescent reaction product to a patient.
... |
| Eflornithine prodrugs, conjugates and salts, and methods of use thereof | 20100120727 | 20100513 |
| In one aspect, the present invention provides a composition of a covalent conjugate of an eflornithine analog with an anti-inflammatory drug. In another aspect, the present invention provides a composition of an eflornithine prodrug. In another aspect, the present invention provides a composition of an eflornithine or its derivatives aspirin salt. In another aspect, the present invention provides methods for treating or preventing cancer using the conjugates or salts of eflornithine analogs or eflornithine prodrugs.
... |
| Combination therapy of substituted oxazolidinones | 20100120718 | 20100513 |
| The present invention relates to combinations of A) oxazolidinones of the formula (I) with B) acetylsalicylic acid (aspirin) and C) an ADP receptor antagonist, in particular P2Y12 purinoreceptor blocker, to a process for producing these combinations and to the use thereof as medicaments, in particular for the prophylaxis and/or treatment of thromboembolic disorders.
... |
| Use of novel lipid mediators to inhibit angiogenesis | 20100105772 | 20100429 |
| The present invention is generally drawn to novel isolated therapeutic agents, termed lipoxins, generated from the interaction between a dietary omega-6 polyunsaturated fatty acid (PUFA) such as arachidonic acid (AA), oxygenases and the analgesic aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy containing derivatives of AA containing compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- and tri-hydroxy derivatives of AA (lipoxins, aspirin-triggered epi-lipoxins) that diminish, prevent, or eliminate NV, hemangiogenesis and/or angiogenic condition(s) of corneal tissue. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.
... |
| Synergistic anti-inflammatory and antioxidant dietary supplement compositions | 20100098676 | 20100422 |
| Disclosed herein are novel dietary supplement compositions comprising enriched 3-O-acetyl-11-keto-β-boswellic acid and enriched demethylated curcuminoids, wherein the composition exhibits anti-inflammatory, antiulcerogenic and antioxidant activities. Also disclosed are novel compositions comprising enriched 3-O-acetyl-11-keto-β-boswellic acid, enriched demethylated curcuminoids that have a synergistic effect on specific inhibition of—COX-2 and 5-LOX activity and optionally containing glucosamine, resveratrol, garlic extract, chondroitin, methlysulphonymethane, bromelain, serratiopeptidase, quercitine, gallic acid, caffeic acid, green tea extract, aspirin and ibuprofen.
... |
| Treatment and prevention of cardiovascular events | 20100068269 | 20100318 |
| A pharmaceutical dosage form for treating or preventing cardiovascular events comprises therapeutic amounts of: a β-adrenergic receptor antagonist, a diuretic, or both; a cholesterol-lowering agent; an inhibitor of the renin-angiotensin system; and aspirin.
... |
| Prevention of neutrophil recruitment | 20100048702 | 20100225 |
| Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II.
... |
| Resolvins: biotemplates for novel therapeutic interventions | 20100016432 | 20100121 |
| The present invention is generally drawn to novel isolated therapeutic agents, termed resolving, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the... |
| Compositions and methods for reducing hepatotoxicity associated with drug administration and treating non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and associated cirrhosis | 20100016262 | 20100121 |
| The present invention relates to the discovery that acetylsalicylic acid (ASA or aspirin), salicylic acid (SA) and related salicylate esters and their pharmaceutically acceptable salts, when coadministered in effective amounts with a drug or other bioactive agent which typically (in the absence of the salicylate compound) produces significant hepatotoxicity as a secondary indication, will substantially reduce or even eliminate such hepatotoxicity. Favorable therapeutic intervention results from the use of the present invention having the effect of reducing hepatotoxicity associated with the administration of certain drugs and other bioactive agents and in certain instances of allowing the administration of higher doses of a compound which, without the coadministration, would produce hepatotoxicity which limits or even negates the therapeutic value of the compound. The invention also relates inter... |
| Niacin and nsaid combination therapy | 20100015220 | 20100121 |
| Provided are pharmaceutical compositions and methods for preventing or reducing niacin-induced flushing comprising an aspirin component and a niacin component having different release profiles. Also provided are methods and compositions for preventing or reducing niacin-induced flushing comprising niacin, aspirin and a lipid-lowering drug other than niacin.
... |
| Compositions and methods for reducing hepatotoxicity associated with drug administration and treating non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and associated cirrhosis | 20090239831 | 20090924 |
| The present invention relates to the discovery that acetylsalicylic acid (ASA or aspirin), salicylic acid (SA) and related salicylate esters and their pharmaceutically acceptable salts, when coadministered in effective amounts with a drug or other bioactive agent which typically (in the absence of the salicylate compound) produces significant hepatotoxicity as a secondary indication, will substantially reduce or even eliminate such hepatotoxicity. Favorable therapeutic intervention results from the use of the present invention having the effect of reducing hepatotoxicity associated with the administration of certain drugs and other bioactive agents and in certain instances of allowing the administration of higher doses of a compound which, without the coadministration, would produce hepatotoxicity which limits or even negates the therapeutic value of the compound. The invention also relates to... |
| Rule-based programming languages for entities in environments | 20090210372 | 20090820 |
| A rule-based programming language may be devised for programming an entity in an environment. Computer systems may therefore be configured to program the entity with at least one rule comprising at least zero language conditions representing an action condition, at least one language verb representing an action, and at least zero language verb parameters representing an action object. The computer system may also be configured to facilitate entry by a user of a rule set according to the rule-based programming language by receiving user selections of language conditions, language verbs, and language verb parameters. By facilitating the programming by users of entities within environments, the computer system may facilitate individuals (such as non-technical individuals, aspiring programmers, and children) in understanding programming concepts, encourage the development of... |
| Rule-based programming languages for entities in environments | 20090210372 | 20090820 |
| A rule-based programming language may be devised for programming an entity in an environment. Computer systems may therefore be configured to program the entity with at least one rule comprising at least zero language conditions representing an action condition, at least one language verb representing an action, and at least zero language verb parameters representing an action object. The computer system may also be configured to facilitate entry by a user of a rule set according to the rule-based programming language by receiving user selections of language conditions, language verbs, and language verb parameters. By facilitating the programming by users of entities within environments, the computer system may facilitate individuals (such as non-technical individuals, aspiring programmers, and children) in understanding programming concepts, encourage the development of... |
| Aspirin-triggered lipid mediators | 20090149538 | 20090611 |
| Aspirin triggered lipid mediators (ATLMs) are disclosed which are useful for the treatment of prevention of inflammation associated with various diseases, including ischemia.
... |
| Room temperature stable non-crystalline aspirin and method for the preparation thereof | 20090131710 | 20090521 |
| The present invention provides stable non-crystalline aspirin that does not crystallize at room temperature during storage for prolonged periods of time and processes for obtaining the stable non-crystalline aspirin.
... |
| Use of sodium channel blocking compounds and aspirin in manufacturing drugs for producing analgesia synergistically in mammals | 20090105197 | 20090423 |
| This invention relates to the use of combinations of a sodium channel blocking compound that binds to an SSI or SS2 site of extracellular region of a sodium channel alpha subunit, and aspirin in manufacturing drugs for producing synergistically analgesic effect in mammals. Pharmaceutical compositions based upon this invention can enhance analgesic effect and reduce dosage of aspirin, therefore side effects and adverse reactions are decreased accordingly.
... |
| Composition and method for treatment and prevention of atherosclerosis | 20090098201 | 20090416 |
| This invention relates to an oral composition for treatment or prevention of atherosclerosis comprising a low-dose aspirin and a low-dose of statin wherein the aspirin and statin are in a slow-release formulation. The invention also relates to a method of treatment or prevention of atherosclerosis using such a composition.
... |
| Pharmaceutical combinations containing an inhibitor of platelet aggregation and a fibrate | 20090062240 | 20090305 |
| The present invention relates to a novel pharmaceutical combination, containing an inhibitor of platelet aggregation and a fÊbrate, where the inhibitor of platelet aggregation is preferably either aspirin or clopidogreL Such a pharmaceutical combination of an inhibitor of platelet aggregation and a fÊbrate is expected to be useful in the treatment and/or prevention of myocardial infarction (heart attack), cardiac arrest, peripheral vascular disease (including symptomatic carotid artery disease), congestive heart failure, ischemic heart disease, angina pectoris (including unstable angina), sudden cardiac death, unstable angina, as well as cerebrovascular events such as cerebral infarction, cerebral thrombosis, cerebral ischemia and transient ischemic attack, disorders related to bypass operations (angioplasty), fitting of endovascular prostheses and restenosis, and inflammatory disorders, including arthritic conditions such as rheumatoid arthritis and osteoarthritis, as... |
| Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor | 20090048216 | 20090219 |
| alone or in combination with a second agent which can be aspirin or a thrombolytic agent.
... |
| Tooth for tooth model, comprising enamel portion impregnated with resin or low melting point glass, and method for producing the same | 20090035738 | 20090205 |
| An object of the present invention is to provide a tooth model capable of exhibiting grinding feel similar to that of a natural tooth, with which students aspiring to become dentists experience intraoral work and perform training related to a treatment, and also experience formation of an abutment tooth, formation of cavity or the like. A difference in the grinding feel between tooth enamel and dentin, which constitute a natural tooth, is reproduced by impregnating a sintered body formed integrally of an inorganic powder such as alumina with a thermosetting resin or a low melting point glass to form an enamel portion.
... |
| Multifunctional and combinational application of aspartame and or futhan | 20090036528 | 20090205 |
| The present invention is an application, composition, and method of using a pharmaceutically effective amount of aspartame or its primary metabolite aspartyl-phenylalanine in systematic and periodic application or dose as an aspirin (NSAID) substitute, treatment for osteoporosis, and or topical treatment for Rosacea.
... |
| Unique combination of acetylsalicylic acid, ethylenediamine dihydroiodide (eddi), and buffer for use in animal drinking water | 20090029952 | 20090129 |
| A unique combinations include acetylsalicylic acid (aspirin), ethylenediamine dihydriodide (EDDI), potassium iodide, sodium acetate, and sodium diacetate, useful in helping poultry, swine, and cattle overcome certain symptoms after vaccination. The inventive combinations readily dissolve in water at room temperature to form an effective concentration for inclusion in the animal's drinking water.
... |
| Compositions for inhibiting and preventing vascular occlusion containing nutritional supplements | 20090023692 | 20090122 |
| Compositions for inhibiting vascular occlusion in humans comprising aspirin for inhibiting vascular occlusion which further contain nutritional supplements are disclosed. The compositions are provide in a dosage form that provides stability of the active ingredient allowing for improved shelf life. A further composition included a cholesterol-lowering agent in combination with aspirin and optionally with nutritional supplements.
... |
| Use of tp modulators for the treatment of cardiovascular disorders in aspirin sensitive and other populations | 20090012115 | 20090108 |
| The present invention provides methods and compositions useful in the treatment or prevention of cardiovascular disorders in individuals for whom therapy with a COX-1 enzyme inhibitor is not feasible due to sensitivity, intolerance, or resistance to the inhibitor. Additionally, the invention provides methods of treating cardiovascular disorders in an individual who is receiving a therapeutically effective dose of a TP modulator and is instructed or advised to avoid and/or not to take aspirin or another COX-1 inhibitor.
... |
| Have-a-heart | 20090000980 | 20090101 |
| A heart shaped container, designed to attach to your key ring. In the event of a suspected heart attack, a person places his or her thumb under the protruding tab and index finger on the top of the other tab. When pressure is applied the hinged snap on lid separates, except for the hinge, from the base. This, will make immediately accessible the suggested load of two 325 mg aspirin sitting in the pill cradles of the container base. By inverting the Have-A-Heart unit the two aspirin release into the awaiting hand, and the user then ingests one of these. The user thereby increases dramatically the chance of surviving the heart attack and greatly reduces the damage to the heart muscle. When immediate action is necessary... |
| High shear process for aspirin production | 20090005592 | 20090101 |
| Use of a high shear mechanical device in a process for production of acetyl salicylic acid, by contacting acetic anhydride with salicylic acid in a high shear device. The disclosed process makes possible a decrease in mass transfer limitations, thereby enhancing production of acetyl salicylic acid. A system for production of acetyl salicylic acid is also provided in which a reactor is configured to receive the output from a high shear device, which is configured to receive, via one or more inlets, acetic anhydride, and salicylic acid and generate a fine dispersion or emulsion of reactants.
... |
| Compositions for preventing and reducing delayed onset muscle soreness | 20080317886 | 20081225 |
| The present invention relates to the compositions that enhance post-exercise recovery processes to increase both strength and muscle mass, replace glycogen stores, and prevent inflammation, resulting in the prevention and/or reduction of delayed onset muscle soreness. Additionally, it provides a feeling of muscle relaxation as well as a feeling of mental tranquility immediately following exercise. The composition consists of any or all high-glycemic sugars and/or polysaccharides (e.g., sucrose, glucose, maltodextrin), all essential amino acids and beta-hydroxy-beta-methylbutyrate and can include other amino acids sources (e.g. whey protein), performance enhancing agents (e.g., caffeine, L-glutamate), anti-inflammatory agents (e.g., ginger, boswellia, curcumen), antioxidants (vitamin C, vitamin E, selenium, polyphenols,), insulin-mimicking agents (cinnamon, Banaba), analgesics (e.g. aspirin, ibuprofen, naproxen, acetaminophen), and to methods of treating humans and animals by administration of... |
| Novel polymorph of acetylsalicylic acid, and methods of making and using the same | 20080319068 | 20081225 |
| A polymer of aspirin is provided by the present invention. Methods of making and using the same are also provided.
... |
| Ischemic stroke therapy | 20080319355 | 20081225 |
| A method for delivering ultrasound energy to a patient's intracranial space includes the steps of forming a hole in a patient's skull, locating an ultrasound transmitter near or into the hole, and transmitting ultrasound from the transmitter into the intracranial space, wherein the Mechanical Index of ultrasound energy traveling through cerebral tissue in the intracranial space is less than 1.0, the power intensity delivered to a target tissue in the intracranial space is greater than 50 mW/cm2 and less than 200 mW/cm2, and the frequency of the transmitted ultrasound is within the range between 500 kHz and 2 MHz. Microbubbles, aspirin, both microbubbles and aspirin, and a mixture of microbubbles and aspirin, can also be delivered into the intracranial space.
... |
| Inhibition of tnf-alpha-initiated response | 20080312323 | 20081218 |
| The impact of lipoxin A4 (LXA4) and aspirin-triggered-lipoxins (ATL) was investigated in tumor necrosis factor (TNFα)-initiated neutrophil (PMN) responses in vitro and in vivo using metabolically stable LX analogs. At concentrations as low as 1-10 nM, the LXA4 and ATL analogs each inhibited TNFα-stimulated superoxide anion generation and IL-1β release by human PMN.
... |
| Treatment of aspirin resistance with radix salviae miltiorrhizae, its extract and composition | 20080305189 | 20081211 |
| The present invention relates to the treatment of aspirin resistant cardio-cerebrovascular diseases using RSM (RSM), its extract and composition comprising any or both of them, especially the formulation Dan Shen Drop Pills (Drop Pills of RSM).
... |
| Methods of screening for compounds that modulate tafia activity, compounds, and methods of using the compounds | 20080305508 | 20081211 |
| Provided are methods of screening compounds for any aspirin-related activity other than TAFI inhibition, and also for non-inhibition of TAFI. Compounds identified by the screening methods can be used to treat, prevent or manage in a patient pain, fever, colon cancer, pancreatic cancer or an inflammatory, platelet aggregation, fibrinolytic or hemorrhagic disease or disorder. Also provided is a method of evaluating test compounds for TAFI inhibitory activity wherein the TAFI inhibitory activity of these test compounds is compared to the TAFI inhibitory activity of aspirin or its derivatives or metabolites. Further provided is a method of treating, preventing or managing in a patient, a hemorrhagic or thrombotic disease or disorder with high dose aspirin or aspirin derivatives or metabolites. Also contemplated is a method of treating,... |
| Method for the diagnosis of aspirin intolerance | 20080293047 | 20081127 |
| c. the expression of at least one of said target genes is determined.
... |
| Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events | 20080287403 | 20081120 |
| Use of an inhibitor of the renin-angiotensin system or a pharmaceutically acceptable derivative thereof, optionally together with an other antihypertensive, a cholesterol lowering agent, a diuretic or aspirin, in the manufacture of a medicament for the prevention of cardiovascular events; a method of preventing cardiovascular events comprising administering to a patient in need of such prevention an effective amount of an inhibitor of the renin angiotensin system or a pharmaceutically acceptable derivative thereof, optionally together with an other antihypertensive, a cholesterol lowering agent, a diuretic or aspirin; and a combination product containing an an inhibitor of the renin-angiotensin system or a pharmaceutically acceptable derivative thereof and a cholesterol lowering agent.
... |
| Method and device for monitoring aspirin response | 20080254491 | 20081016 |
| The invention provides a method of monitoring the response of platelets to a COX1 inhibitor such as aspirin. The method involves collecting platelet-containing mammalian blood treated with a COX 1 inhibitor; mixing the blood with a COX 1-dependent platelet agonist, such as arachidonic acid, monitoring extracellular ATP in the agonist-activated bl>>d to generate a measurement, and comparing the measurement to a standard value. Devices, systems, and kits for carrying out the method are also provided.
... |
| Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors | 20080242643 | 20081002 |
| The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H)-furanones useful in the treatment of cyclooxygenase-2 mediated diseases. Formula (I). The invention also encompasses certain pharmaceutical compositions and methods for treating cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula 1. The above compounds may be used as a combination therapy with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions while also reducing the risk of thrombotic cardiovascular events.
... |
| Combination therapy for treating cyclooxygenase-2 mediated diseases or conditions in patients at risk of thrombotic cardiovascular events | 20080242722 | 20081002 |
| or a pharmaceutically acceptable salt thereof, wherein the nitric oxide donating compound is administered in an amount effective to reduce the gastrointestinal toxicity caused by the combination of the cyclooxygenase-2 selective inhibitor and aspirin. Pharmaceutical compositions are also encompassed.
... |
| Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors | 20080227758 | 20080918 |
| The invention also encompasses certain pharmaceutical compositions and methods for treating cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula I. The above compounds may be used as a combination therapy with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions while also reducing the risk of thrombotic cardiovascular events.
... |
| Novel nsaids possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety | 20080214646 | 20080904 |
| This invention provides a prodrug that help arthritis patients without increasing cardiovascular and gastrointestinal risk. A novel group of hybrid nitric oxide-releasing non-steroidal anti-inflammatory drugs (NO-NSAIDs), moiety attached via a one -carbon methylene spacer to the carboxylic acid group of the traditional NSAIDs aspirin, ibuprofen and indomethacin were synthesized. The ester prodrugs showed equipotent anti-inflammatory activities in vivo to that of the parent aspirin, ibuprofen and indomethacin. The simultaneous release of parent drug and nitric oxide from the NO- prodrugs constitutes a potentially beneficial property for the prophylactic prevention of thrombus formation and adverse cardiovascular events such as stroke and myocardial infarction. Data acquired in an in vivo ulcer index (UI) assay showed that this group of ester prodrugs in which no lesions were observed when... |
| Device and methods for identifying and treating aspirin non-responsive patients | 20080207681 | 20080828 |
| The present invention relates to methods and compositions for identifying and treating subjects in need of antithrombotic therapies but who are not responsive to aspirin.
... |
| Efficient method for producing compositions enriched in total phenols | 20080199548 | 20080821 |
| A product made by a process which results in compositions enriched in total phenols includes purification steps not involving the addition of bisulfite ions. The enriched compositions are characterized as containing monomeric, oligomeric and polymeric phenols, total phenol concentration >12% and exhibiting in vitro COX-2 inhibitory activity enhanced by a factor of at least 2.5 over a standard aspirin dose of 660 μg/mL.
... |
| Solid oral formulations for combination therapy | 20080166407 | 20080710 |
| Multifunctional, single, bilayer, and trilayer coated tablets for combination therapy are formed wherein the bioactive agents responsible for the therapeutic multifunctionality are present as a combination of a gastric acid-reducing agent, such as omeprazole and ranitidine, and at least one analgesic/anti-inflammatory agent, such as acetaminophen, naproxen sodium, ibuprofen, tolmetin, and aspirin.
... |
| Method and device for monitoring inhibition of platelet function | 20080166744 | 20080710 |
| The invention provides a method of monitoring the response of platelets to a COX1 inhibitor such as aspirin. The method involves collecting platelet-containing mammalian blood treated with a COX1 inhibitor; mixing the blood with a COX1-dependent platelet agonist, such as arachidonic acid, monitoring extracellular ATP in the agonist-activated blood to generate a measurement, and comparing the measurement to a standard value. Devices, systems, and kits for carrying out the method are also provided.
... |
| Disposable cup containing dry beverage food or medicament ingredients in liquid permeable bag heat welded to its inner surface | 20080152768 | 20080626 |
| The bag is fashioned with a seam along one side and at least a small portion or spot of that seam line is vacuum welded at a temperature between 100° C. and 200° C. and a frequency of about 20,000 kilohertz to the bottom of the cup form a permanent bond. When hot or cold liquid is added to the cup, the bag containing the desired dry beverage precursor, dry food precursor, or dried medicament floats freely from the spit at which it is welded so that the circulating liquid passes through the bag and becomes thoroughly mixed with the contents of the bag to produce the desired beverage, food (especially soup) or diluted medicament which is easily drunk or otherwise consumed from the cup. The... |
| Methods and compositions for reducing the risk of adverse cardiovascular events associated with the administration of artificial blood | 20080118572 | 20080522 |
| Methods and compositions are provided for reducing the risk of adverse cardiovascular (CV) events associated with the administration of artificial blood. The methods involve the administration of a composition comprising artificial blood and one or more preventative pharmaceutical agents for reducing the risk of adverse CV events. In specific embodiments, an agent is selected from the group consisting of hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins), angiotensin converting enzyme (ACE) inhibitors, aspirin, corticosteroids, PPAR agents, and vasodilators. Kits for administering artificial blood together with one or more pharmaceutical agents that reduce the risk of adverse CV events are also provided.
... |
| Treatment of inflammatory, cancer, and thrombosis disorders | 20080113951 | 20080515 |
| A pharmaceutical composition and a method of treating inflammation in a mammal. The method administers the therapeutic composition to the mammal. The therapeutic composition includes: a standard therapeutic dose of a COX2 inhibitor consisting of celecoxib or rofecoxib; and low dose aspirin in an amount of 70-85 mg.
... |
| Method of treatment with coadministration of aspirin and prasugrel | 20080108589 | 20080508 |
| A method for the prevention of diseases caused by thrombus or embolus. The method is to separately administer 2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, in their pharmacologically effective amounts, to a warm-blooded animal.
... |
| Combination therapy for treating cyclooxygenase-2 mediated diseases or conditions in patients at risk of thrombotic cardiovascular events | 20080096927 | 20080424 |
| The invention encompasses a pharmaceutical composition comprising a therapeutically effective amount of a cyclooxygenase-2 selective inhibitor selected from rofecoxib and etoricoxib or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a proton pump inhibitor selected from the group consisting of: omeprazole, lansoprazole, rabeprazole, pantoprazole, and esomeprazole, or a pharmaceutically acceptable salt of any of the aforementioned, in combination with a pharmaceutically acceptable carrier. The invention also encompasses a method for treating a cyclooxygenase-2 mediated disease or condition in a human patient at risk of a thrombotic cardiovascular event, wherein the patient is on aspirin therapy to reduce the risk of the thrombotic cardiovascular event, comprising administering to the patient this pharmaceutical composition.
... |
| Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma | 20080096961 | 20080424 |
| The present invention is generally drawn to novel isolated therapeutic agents, termed resolving, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the... |
| Inhibition of tnf-alpha-initiated neutrophil response | 20080081838 | 20080403 |
| The impact of lipoxin A4 (LXA4) and aspirin-triggered-lipoxins (ATL) was investigated in tumor necrosis factor (TNFα)-initiated neutrophil (PMN) responses in vitro and in vivo using metabolically stable LX analogs. At concentrations as low as 1-10 nM, the LXA4 and ATL analogs each inhibited TNFα-stimulated superoxide anion generation and IL-1β release by human PMN.
... |
| Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases | 20080064746 | 20080313 |
| The use of lipoxin analogs for the treatment or prevention of asthma and asthma related diseases is described. In particular, acetylenic lipoxin analogs are effective for the treatment and prevention of eosinophil recruitment involved with the inflammation processes associated with asthma, asthma like conditions, and lung injuries associated from airway inflammation or infection as brought about by leukocyte-mediated injury from within.
... |
| Prevention of neutrophil recruitment | 20080064747 | 20080313 |
| Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II.
... |
| Uses of selective cyclooxygenase-1 inhibitors | 20080051417 | 20080228 |
| The present invention discloses effect of non-selective COX1 inhibitor such as aspirin, statins, thiazolidinediones or combinations thereof on COX2. Also disclosed herein is a method to avoid the adverse effects that the non-selective COX1 inhibitor may have when administered with statins and/or thiazolidinediones.
... |
| Method to treat gastric lesions | 20080027022 | 20080131 |
| The present invention provides a therapeutic method for treating gastric lesions, including administration to a patient in need thereof of an effective amount of an A2A adenosine receptor agonist. The A2A adenosine receptor agonist can be a compound of formula (I) as disclosed herein. The invention further provides a therapeutic method for treating the patient with an A2A adenosine receptor agonist, optionally, in combination with a Type IV phosphodiesterase (PDE) inhibitor. In one embodiment, the gastric lesions are caused by, or aggravated by, the use of NSAIDS such as, for example, aspirin.
... |
| Combinations comprising cox-2 inhibitors and aspirin | 20080027032 | 20080131 |
| A pharmaceutical composition is provided for treatment of conditions in mammals which are responsive to COX-2 inhibition which comprises in combination a COX-2 inhibitor and low-dose aspirin for simultaneous, sequential or separate use
... |
| Apparatus for carrying heart related medication | 20080006556 | 20080110 |
| An apparatus for holding one of aspirin, nitroglycerine or other emergency medication for a person who may be at risk for a heart attack. The apparatus comprises a key shaped member having a predetermined length. Such key shaped member has an aperture disposed through a first end of the key shaped member for engagement with a key ring. There is a pill holder for carrying such one of aspirin, nitroglycerine and other emergency medication and having a predetermined shape and a predetermined size, such pill holder is engageable with a second end of the key shaped member. A lid member is engageable with such pill holder for firmly holding such one of aspirin, nitroglycerine and other emergency medication disposed in the pill holder and a snap... |
| Analgesic/antipyretic compositions for enhanced absorption | 20070298096 | 20071227 |
| The onset of activity of a first analgesic/antipyretic composition containing an analgesic/antipyretic effective amount of acetaminophen, caffeine and, optionally, aspirin is shortened by incorporating in the first composition an onset of analgesic/antipyretic activity shortening amount of at least one alkaline agent whereby a second composition is produced. The second composition being bioequivalent to the first composition but having a shorter onset of analgesic/antipyretic activity than the first composition.
... |
| Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers | 20070292498 | 20071220 |
| Pharmaceutical compositions comprising a proton pump inhibitor, one or more buffering agent, a sleep aid and acetaminophen, ibuprofen, aspirin or naproxen are described. Methods are described for treating gastric acid related disorders and inducing sleep, using pharmaceutical compositions comprising a proton pump inhibitor, a buffering agent, a sleep aid and a pain reliever.
... |
| Composition and methods for the treatment of joint pain using angelica gigas nakai extract and powder as combined with glucosamine sulfate, or chondroitin sulfate and hcl, or msm, or aspirin, or celedrin, and as combinations thereof in powder, pill, capsu | 20070264370 | 20071115 |
| The present invention relates to composition comprising dry powder of decursinol, decursin, and their related derivates isolated from the roots of Angelica gigas Nakai (Korean Angelica) plant and at least one of joint improvement agents such as glucosamine, chondroitin, or methylsulfonylmethane (MSM). The present invention is directed to methods, combinations, and compositions for treating, preventing or reducing the joint pain or the symptoms associated with, or related to, a joint disorder or disease in a subject in need thereof.
... |
| Prevention of neutrophil recruitment | 20070259958 | 20071108 |
| Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II.
... |
| Methods and kits for detection of thromboxane a2 metabolites | 20070202556 | 20070830 |
| Methods, compositions and kits are provided for measuring aspirin's anti-thrombotic effectiveness on a subject. Included are a novel assay for quickly and specifically measuring TxA2 metabolite levels in urine and correlating the levels with aspirin dose in a subject. The methods, compositions and kits utilize a novel anti TxA2 metabolite antibody.
... |
| Karaoke system which displays musical notes and lyrical content | 20070186755 | 20070816 |
| A karaoke system which displays and highlights musical notes and tablature, in addition to lyrics, as they are to be played or sung, with a view to helping an aspiring musician learn to play their instrument of choice. The system further utilizes a means to slow the tempo of the songs being played, so that the aspiring musician can master the notes and timing of the songs. The system can be patched to any TV system or displayed on the screen of the system itself The system contains an amp which allows for the plugging in of electric instruments and features a built in microphone. The system further allows a musician the option of a “full band” backup when the song is played, or the option... |
| Aspirin formulation for cardiovascular health | 20070166412 | 20070719 |
| The invention relates generally to an aspirin formulation which may comprise additional vitamins, minerals, herbs and supplements and methods for using the same for maintaining cardiovascular health. The aspirin formulation may comprise supplements such as vitamin B6, vitamin B12, folic acid, arginine and garlic. The invention also encompasses methods for maintaining healthy blood pressure and cholesterol levels with the aspirin formulation described herein.
... |
| Aspirin formulation for cardiovascular health | 20070160661 | 20070712 |
| The invention relates generally to an aspirin formulation which may comprise additional vitamins, minerals, herbs and supplements and methods for using the same for maintaining cardiovascular health. The aspirin formulation may comprise supplements such as vitamin B6, vitamin B12, folic acid, arginine and garlic. The invention also encompasses methods for maintaining healthy blood pressure and cholesterol levels with the aspirin formulation described herein.
... |
| Coumarin analog compounds for safer anticoagulant treatment | 20070155828 | 20070705 |
| The present invention relates to the albumin-guided development of coumarin analogs and the analogs developed thereby. The coumarin analogs of the present invention are identified and isolated by the fact that they have binding sites to albumin which are different than the binding sites of conventional coumarin analogs such as sodium warfarin, and as a result will be less prone to be displaced since the binding site of sodium warfarin is shared by numerous drugs such as aspirin. The coumarin analogs of the invention are advantageous because they can achieve the effects of the prior coumarin analogs with a minimum of metabolic complications and undesirable side effects.
... |
| Molecular delivery to cells using aspirin-related compounds | 20070122908 | 20070531 |
| The present invention provides for a system and method whereby aspirin and acetic acid help to permeabilize cell membranes to allow exogenous molecules to gain access to the cell interior. As such, the present invention provides a low cost drug and gene delivery tool that can be applied in combination with other molecular delivery methods.
... |
| Water-soluble aspirin composition | 20070092561 | 20070426 |
| Compositions in which aspirin is present in combination with alkaline compounds, especially those containing water of crystallization (hydrates), deteriorate on standing. This deterioration may take several forms: It can be a physical deterioration in which such aspirin compositions become completely unmanageable, wet, gummy, sticky masses; or chemical decomposition in which aspirin loses its molecular structure chiefly by losing the acetyl group. The latter is accompanied by formation of acetic acid, the mixture developing its characteristic acetic odor. In both cases, such compositions become entirely unsuitable for all practical commercial and medicinal purposes. Yet, when preparation of water-soluble aspirin compositions is desired, it is impossible to avoid the use of alkaline compounds. This is because the only known method of converting aspirin into soluble form is by... |
| Treatment of aspirin resistance with radix salviae mitiorhizae, its extract and composition | 20070071837 | 20070329 |
| The present invention relates to the treatment of aspirin resistant cardio-cerebrovascular diseases using RSM (RSM), its extract and composition comprising any or both of them, especially the formulation Dan Shen Drop Pills (Drop Pills of RSM).
... |
| Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen | 20070059356 | 20070315 |
| A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphinic acid, phosphonic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, 0-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.
... |
| Methods and kits for co-administration of nutritional supplements | 20070053892 | 20070308 |
| The present invention relates to methods of co-administration of various vitamin, mineral and aspirin compositions, and in a specific embodiment, comprise co-administering one composition comprising vitamin B6, vitamin B12, folic acid, and CoQ10 and a second composition comprising aspirin for nutritional supplementation and drug therapy in order to prevent, treat and/or alleviate the occurrence or negative effects of cardiovascular disease; and kits provided for co-administration of various vitamin, mineral and drug compositions, and in a specific embodiment, comprise one composition comprising vitamin B6, vitamin B12, folic acid, and CoQ10 and a second composition comprising aspirin for nutritional supplementation and drug therapy in order to prevent, treat and/or alleviate the occurrence or negative effects of cardiovascular disease.
... |
| Aqueous solution of an analgesic and a dispenser therefor | 20070045134 | 20070301 |
| A bottle cap is adapted to retain a quantity of an additive, such as for example aspirin or the like. The additive is retained in an isolated condition within a sealed chamber or within a bladder inside the bottle cap but in fluid communication with the liquid within the bottle, such as water. Means are provided to breech the seal of the chamber or the bladder, thereby releasing some or all of the additive retained within the bottle cap.
... |
| Aspirin-triggered lipid mediators | 20070049639 | 20070301 |
| Aspirin triggered lipid mediators (ATLMs) are disclosed which are useful for the treatment of prevention of inflammation associated with various diseases, including ischemia.
... |
| Fuel economy additive | 20070028508 | 20070208 |
| A fuel additive to significantly improve fuel economy of internal combustion engines, a process of making the additive (10) and a process of using the additive (20). The fuel additive is aspirin dissolved in a carrier fluid that is miscible in gasoline or diesel fuel. The process of making involves a step of mixing aspirin with a carrier fluid, which dissolves the aspirin and which is thereafter miscible in gasoline or diesel fuel. A preferred carrier fluid is ethyl alcohol. The process of using involves a step of adding that mixture to the fuel serving the internal combustion engine.
... |
| Compositions for reducing the incidence of drug induced arrhythmia | 20070021395 | 20070125 |
| In accordance with the present invention, novel methods and formulations are provided for treating and preventing the incidence of drug-induced pro-arrhythmia, including torsades de pointes. The methods and formulations comprise a combination of a drug that induces torsade de pointes, such as Class III antiarrhythmics, certain antimicrobials, antihistamines, antidepressants, antipsychotics, diuretics, with an aspirin and/or a statin. In certain embodiments, the compositions and methods for treatment comprise azimilide and aspirin and/or a statin. These compositions may be administered by different routes, including orally. In certain embodiments where the antiarrhythmic is azimilide it may be administered orally in a dose of about 25 mg to about 300 mg.
... |
| Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events | 20070021491 | 20070125 |
| Use of an inhibitor of the renin-angiotensin system or a pharmaceutically acceptable derivative thereof, optionally together with another antihypertensive, a cholesterol lowering agent, a diuretic or aspirin, in the manufacture of a medicament for the prevention of cardiovascular events; a method of preventing cardiovascular events comprising administering to a patient in need of such prevention an effective amount of an inhibitor of the renin angiotensin system or a pharmaceutically acceptable derivative thereof, optionally together with another antihypertensive, a cholesterol lowering agent, a diuretic or aspirin; and a combination product containing an an inhibitor of the renin-angiotensin system or a pharmaceutically acceptable derivative thereof and a cholesterol lowering agent.
... |
| Medicinal compositions containing aspirin | 20070010499 | 20070111 |
| A combination of 2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, which possess excellent inhibitory activity against platelet aggregation and thrombogenesis, and is useful for preventing or treating diseases caused by thrombus or embolus.
... |
| Nanoparticulate clopidogrel and aspirin combination formulations | 20070003615 | 20070104 |
| The present invention is directed to compositions comprising a nanoparticulate clopidogrel and aspirin combination, or salts or derivatives thereof, having improved clopidogrel bioavailability. The nanoparticulate clopidogrel particles, and optionally the nanoparticulate aspirin particles, of the composition have an effective average particle size of less than about 2000 nm and are useful in the prevention and treatment of pathologies induced by platelet aggregation. The clopidogrel and aspirin particles may also be formulated as a controlled release polymeric coating or matrix drug delivery system.
... |
| Use of resolvins to treat gastrointestinal diseases | 20060293288 | 20061228 |
| The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), oxygenases and the analgesic aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy containing derivatives of EPA and DHA containing compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- and tri-hydroxy derivatives of EPA or DHA (resolvins of the E series and D series) that diminish, prevent, or eliminate gastrointestinal conditions, for example, such as colitis. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for... |
| Efficient method for producing compositions enriched in total phenols | 20060280816 | 20061214 |
| A product made by a process which results in compositions enriched in total phenols includes purification steps not involving the addition of bisulfite ions. The enriched compositions are characterized as containing monomeric, oligomeric and polymeric phenols, total phenol concentration >12% and exhibiting in vitro COX-2 inhibitory activity enhanced by a factor of at least 2.5 over a standard aspirin dose of 660 μg/mL.
... |
| Method and system for stabilization of arachidonic acid for use in platelet function assay | 20060246527 | 20061102 |
| Methods and systems for rapidly determining the level of platelet inhibition in whole blood, due to aspirin usage, with a single use arachidonic based assay device that can be stored at room temperature is provided. A lyophilized assay reagent that contains arachidonic acid at sufficient concentration to maximally activate platelets is utilized. An antioxidant within the same lyophilized assay reagent reduces the oxidation rate of arachidonic acid but does not interfer with platelet function. An oxygen absorber within the single use assay device packaging creates an inert environment within a short period of time after package is sealed. The assay device can have a housing with a plurality of channels and a common blood sample introduction port coupled to each of a channel of the plurality... |
| Method for treating a mammal by administration of a compound having the ability to release co | 20060233890 | 20061019 |
| Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.
... |
| Blowing device | 20060223675 | 20061005 |
| A blowing device useful for acquisition of blowing and/or aspiring abilities, wherein the user is directed to blow and/or aspire is a predetemined manner. This novel devise comprising an envelope; at least one movable element located inside the inner portion of said envelope; a maneuverable tube of an open bore, having a proximal portion and a distal portion; said tube is protruded into said envelope at the proximal end and extended to a mouthpiece, adapted to be in communication with said user mouth; the distal portion of said tube is further extended into the inner portion of the envelope; wherein said movable element is directed to move in a predetermined course by a means of the blowing and/or aspiration characteristics.
... |
| Method for treating thrombosis | 20060217352 | 20060928 |
| This invention relates to a method for treating thrombosis by combined administration of a pitavastatin with aspirin.
... |
| Composition for mitigating a pernicious thrombotic event | 20060182732 | 20060817 |
| A composition. The composition comprises aspirin, magnesium, and nattokinase, and either niacin or nitroglycerine. The composition has a structural form of: a chewable form, a dissolvable form, a liquid form, a spray form, or a suppository form. The structural form is suitable for being introduced into the body of a person, such as by means of a body cavity of the person. The composition may be used for mitigating adverse effects of an imminent or actually-occurring pernicious thrombotic event, such as a heart attack or stroke, in the person.
... |
| Device and methods for identifying and treating aspirin non-responsive patients | 20060160165 | 20060720 |
| The present invention relates to methods and compositions for identifying and treating subjects in need of antithrombotic therapies but who are not responsive to aspirin.
... |
| Hemiterpene glycosides with anti-platelet aggregation activities from ilex pubescens | 20060154877 | 20060713 |
| Two hitherto unreported novel hemiterpene glycosides were isolated in substantially pure form from the root of Ilex pubescens. The chemical structures and some properties of these hemiterpenes have been elucidated. These hemiterpene glycosides possess anti-platelet aggregation activity more potent than those of salvianolic acid B and aspirin and may be used in pharmaceutical compositions in humans and mammals in need of such treatment.
... |
| Method for treating a mammal by administration of a compound having the ability to release co, compounds having the ability to release co and pharmaceutical compositions thereof | 20060148900 | 20060706 |
| Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.
... |
| Composition containing an association of aspirin and an anti-xa oligosaccharide and use of an anti-xa oligosaccharide optionally in combination with aspirin | 20060122151 | 20060608 |
| The invention relates to the use of a synthetic oligosaccharide which is a selective inhibitor of factor Xa acting via antithrombin III, alone or in association with aspirin, for the preparation of medicaments intended for preventing or treating thromboembolic diseases occurring in a mammal which has undergone a percutaneous transluminal angioplasty. The subject of the invention is moreover pharmaceutical compositions for the treatment or prophylaxy of thromboembolic diseases occurring in a mammal which has undergone a percutaneous transluminal angioplasty, comprising the association of an effective quantity of at least one synthetic oligosaccharide, which is a selective inhibitor of factor Xa acting via antithrombin III, and of an effective quantity of aspirin, optionally mixed with one or more pharmaceutically acceptable excipients.
... |
| Aspirin and vitamin and/or trace element compositions for the amelioration and treatment of vascular disease | 20060084635 | 20060420 |
| A medicament for the amelioration and treatment of vascular disease consisting of aspirin administered in combination with one or more of the vitamins including vitamin A, vitamin B6, vitamin C, vitamin E, and niacin. Alternative embodiments include the administration of aspirin in combination with one or more trace element including selenium zinc, copper, iron, cobalt, and manganese as well as combinations of aspirin, at least one vitamin and at least one trace element.
... |
| Enteric coated aspirin granules comingled with binder | 20060078611 | 20060413 |
| The invention relates to a tablet capable of being chewed or disintegrated in the oral cavity, which comprises an enteric coated granule comprising an intimate mixture of an aspirin active ingredient and at least one binder capable of preferentially absorbing ambient moisture.
... |
| Chewable enteric coated aspirin tablets | 20060078612 | 20060413 |
| The invention relates to a tablet capable of being chewed or disintegrated in the oral cavity, which comprises an enteric coated aspirin active ingredient, and preferably a lightly compressed matrix comprising directly compressible carbohydrate(s) and at least one sweetener.
... |
| Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases | 20060079577 | 20060413 |
| The use of lipoxin analogs for the treatment or prevention of asthma and asthma related diseases is described. In particular, acetylenic lipoxin analogs are effective for the treatment and prevention of eosinophil recruitment involved with the inflammation processes associated with asthma, asthma like conditions, and lung injuries associated from airway inflammation or infection as brought about by leukocyte-mediated injury from within.
... |
